Eyepoint Pharmaceuticals Inc (OQ:EYPT)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 480 Pleasant St Ste B300
WATERTOWN MA 02472-2468
Tel: 1-212-3621200
Website: https://eyepointpharma.com
IR: See website
<
Key People
Jay S. Duker
President, Chief Executive Officer
Nancy S. Lurker
Executive Vice Chairman of the Board
George Elston
Chief Financial Officer, Executive Vice President
Scott Jones
Senior Vice President, Chief Commercial Officer
Dario A. Paggiarino
Senior Vice President, Chief Medical Officer
Marcia Sellos-Moura
Senior Vice President
Michael C. Pine
Chief Corporate Development and Strategy Officer
   
Business Overview
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company's other products include YUTIQ, and DEXYCU.
Financial Overview
For the fiscal year ended 31 December 2023, Eyepoint Pharmaceuticals Inc revenues increased 11% to $46M. Net loss decreased 31% to $70.8M. Revenues reflect United States segment increase of 12% to $45.3M. Lower net loss reflects Impairment of acquired intangible assets decrease from $20.7M (expense) to $0K, Sales and marketing - Balancing value decrease of 52% to $11.4M (expense).
Employees: 121 as of Feb 29, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $489.66M as of Dec 31, 2023
Annual revenue (TTM): $46.02M as of Dec 31, 2023
EBITDA (TTM): -$74.60M as of Dec 31, 2023
Net annual income (TTM): -$70.80M as of Dec 31, 2023
Free cash flow (TTM): -$1.61M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 49,830,792 as of Mar 1, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.